Abstract
IntroductionOsimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used as the first-line treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC). Nevertheless, most cases...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have